

OCT 17 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

Approved for use through 07/01/2008. GPO 000-000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/729,156
Filing Date	12/05/03
First Named Inventor	Wang
Art Unit	
Examiner Name	
Attorney Docket Number	UM-08477

Examiner Name: Attorney Docket Number: IJM-08477

**U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**Examiner  
Signature**

Date Considered

10/29/25

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/729,156
		Filing Date	12/05/03
		First Named Inventor	Wang
		Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	UM-08477

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	10/29/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



FORM PTO-1449 (Modified)				U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08477		Serial No.: 10/729,156	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))				Applicant: Shaomeng Wang et al.					
				Filing Date: 12/5/03				Group Art Unit:	
<b>U.S. PATENT DOCUMENTS</b>									
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee		Class	Subclass	Filing Date	
SJ	1	3,364,242	1/16/68	Johnson et al.		260	420	7/5/63	
	2	3,347,885	10/17/67	Jones et al.		260	412.4	1/3/66	
	3	4,297,341	10/27/81	Waller et al.		424	80	5/9/80	
	4	4,747,979	5/31/88	Gimber et al.		260	412.4	2/14/85	
	5	4,806,568	2/21/89	Vander Jagt et al.		514	522	9/12/95	
	6	5,026,726	6/25/91	Jagt et al.		514	468	12/11/89	
	7	5,059,717	10/22/91	Ibragimov et al.		568	438	7/16/90	
	8	5,077,441	12/31/91	Kuk et al.		568	761	10/5/90	
	9	5,112,637	5/12/92	Hron, Sr. et al.		426	629	11/5/90	
	10	5,260,327	11/9/93	Kim et al.		514	405	8/4/92	
	11	5,277,909	1/11/94	Schmidt et al.		424	195.1	8/24/90	
	12	5,385,936	1/31/95	Flack et al.		514	548	7/12/90	
	13	5,759,837	6/2/98	Kahajda et al.		435	193	1/24/94	
	14	5,780,675	7/14/98	Royer et al.		562	467	4/28/95	
	15	6,113,397	9/5/2000	Flack et al.		514	682	1/27/95	
	16	6,576,660	6/10/03	Liao et al.		514	456	4/28/2000	
	17	6,608,107	8/19/03	Wong et al.		514	548	12/14/01	
	18	2002/0137801A1	9/26/02						
	19	2003/0082101A1	5/1/03						
SJ	20	2003/0119894A1	6/26/03						
<b>FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS</b>									
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation		
							Yes	No	
SJ	21	WO 02/41828 A2	30 May 2002	PCT					
	22	WO 02/47673 A2	20 June 2002	PCT					
	23	EP 0 651 636 B1	26 July 1993	EP					
	24	1 917 341	3 April 1969	Germany				X	
	25	01132542 A	19 Nov. 1987	Japan					
	26	CH 676360 A5	28/12/88	Switzerland				X	
	27	SU 1351915 A1	16/6/82					X	
Examiner: <i>Danby</i>				Date Considered: 10/29/03					
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
32	28	V. Amberger, <i>et al.</i> , Cancer Res., 58:149-158 (1998)		
	29	Wick <i>et al.</i> (W. Wick, <i>et al.</i> , FEBS Lett., 440:419-424 (1998)		
	30	S. Mohanam, <i>et al.</i> , Cancer Res. 53:4143-4147 (1993)		
	31	P. Pedersen, <i>et al.</i> , Cancer Res., 53:5158-5165 (1993)		
	32	Nuria Rubio, Lab Invest, 81:725-734 (2001)		
	33	Fernández <i>et al.</i> , Cell Death Differ., 7:350-359 (2000)		
	34	J. Reed, Nature, 387:773-776 (1997)		
	35	S. Frisch and E. Ruoslahti, Curr. Opin. Cell Biol., 9:701-706 ((1997))		
	36	D. Del Bufalo, <i>et al.</i> , FASEB J., 11:947-953 (1997)		
	37	Razakantoanina <i>et al.</i> Parasitol. Res., 86:665-668 (2000)		
	38	Dao <i>et al.</i> Bioorg. Med. Chem., 11:2001-2006 (2003)		
	39	Deck <i>et al.</i> J. Med. Chem., 34:3301-3305 (1991)		
	40	Przybylski <i>et al.</i> J. Mol. Structure, 611(1-3):193-201 (2002)		
	41	R.E. Royer <i>et al.</i> , J. Med. Chem., 38:2427-2432 (1995)		
	42	R.E. Royer <i>et al.</i> , "Biologically active derivative of gossypol: synthesis and antimalarial activities of peri-acetylated gossylic nitriles.", J. Med. Chem., 29:1799-1801 (1986)		
	43	C.M. Venuti, J. Org. Chem., 46(15):3124-3127 (1981)		
	44	P.C. Meltzer <i>et al.</i> , J. Org. Chem., 50(17):3121-3124 (1985)		
	45	R. Adams <i>et al.</i> , J. Am. Chem. Soc., 60:2193-2204 (1938)		
	46	Le Blanc <i>et al.</i> , "An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines", Pharmacol. Res., 46:551-555 (2002)		
	47	Baumgrass <i>et al.</i> , "Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol", J. Biol. Chem., 276:47914-47921 (2001)		
	48	Shelley <i>et al.</i> , "Structure-activity studies on gossypol in tumor cell lines," Anticancer Drugs, 11:209-216 (2000)		
	49	Sonenberg <i>et al.</i> , "Anti-fertility and other reactions of gossypol analogues", Contraception, 37:247-255, (1988)		
	50	Whaley <i>et al.</i> , "Monkey lactate dehydrogenase-C4 as a model for the interaction of enzymes with gossypol", Contraception, 33:605-616 (1986)		
	51	Dorsett <i>et al.</i> , "Letter: Antiviral activity of gossypol and apogossypol", J. Pharm. Sci., 64:1073-1075 (1975)		
	52	Wu <i>et al.</i> , "Synthesis and antifertility actions of gossypol derivatives and phenol aldehydes", Yao Xue Xue Bao, 24:502-511 (1989)		
	53	Hoffer <i>et al.</i> , "Antifertility, spermicidal and ultrastructural effects of gossypol and derivatives administered orally and by intratesticular injections", Contraception, 37:301-331 (1988)		
	54	Guo <i>et al.</i> , "Synthesis of mono-aldehyde gossypol and its analogues", Yao Xue Xue Bao, 22:597-602 (1987)		
	55	Manmade <i>et al.</i> , "Gossypol. Synthesis and in vitro spermicidal activity of isomeric hemigossypol derivatives", Experientia, 39:1276-1277 (1983)		
	56	Dowd, Chirality, 15:486 (2003)		
	57	Ciesielska <i>et al.</i> , Chem. Phys. Lett. 353:69 (2002)		
	58	Vermel <i>et al.</i> , Antitumor Activity of Gossypol in Experiments on Transplanted Tumours 39-43 (1963)		
59	59	Freedman <i>et al.</i> , Chirality, 15:196 (2003)		
Examiner:	<i>V. Amberger</i>		Date Considered:	10/29/05
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
81	60	J.C. Reed, Pharmacology, 41:501-553 (1997)		
	61	J.C. Reed <i>et al.</i> , J. Cell Biochem., 6:23-32 (1996)		
	62	Z. Han <i>et al.</i> , Cancer Res., 56:621-628 (1996)		
	63	S.W. Muchmore <i>et al.</i> , Nature, 381:335-341 (1996)		
	64	A.M. Petros <i>et al.</i> , Protein Sci., 9:2528-2534 (2000)		
	65	A.M. Petros <i>et al.</i> , Proc. Natl. Acad. Sci. U.S.A., 98:3012-3017 (2001)		
	66	X.M. Yin <i>et al.</i> , Nature, 369:321-323 (1994)		
	67	S.C. Cosulich <i>et al.</i> , Curr. Biol., 7:913-920 (1997)		
	68	A. Sali <i>et al.</i> , Structure, Function, and Genetics, 23:318-326 (1995)		
	69	A. Sali, Curr. Opin. Biotech., 6:437-451 (1995)		
	70	J.L. Wang <i>et al.</i> , Cancer Res., 60:1498-1502 (2000)		
	71	J.L. Wang <i>et al.</i> , Proc. Natl. Acad. Sci. U.S.A., 97:7124-7129 (2000)		
	72	Sattler <i>et al.</i> , Science, 275:983-986 (1997)		
	73	B.R. Brooks <i>et al.</i> , J. Comp. Chem., 4,187-217 (1983)		
	74	P.V.R. Schleyer <i>et al.</i> , CHARMM: The Energy Function and Its Parameterization with an Overview of the Program, in The Encyclopedia of Computational Chemistry, 1:271-277 eds., John Wiley & Sons, Chichester (1998)		
	75	S. Makino and I.D. Kuntz, J. Comput. Chem. 18:1812-1825 (1997)		
	76	I.J. Enyedy <i>et al.</i> , J. Med. Chem., 44:313-4324 (2001)		
	77	Leschev, "Influence of the Extract of Eleutherococcus senticosus on development of experimental pituitary adenomas in rats", Institute of Oncology of the U.S.S.R. Academy of Medical Sciences, 60-67 (1966)		
	78	Willemsen, An Oxazoline-Based Approach to the Total Asymmetric Synthesis of (S)-Gossypol, UMI PROQuest Digital Dissertations - Full Citation & Abstract		
	79	La Blanc <i>et al.</i> , An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines, Pharmacol. Res. 46(6):551-5 (2002)		
	80	Griffith <i>et al.</i> , Bioenvision Successfully Completes Formulation Research to Develop Gossypol as a Novel Anti-Cancer Agent, Bioenvision News (2003)		
	81	Saydachmov <i>et al.</i> , Uebekskii Khimicheski Zhumal (1):11-13 (1994)		
	82	Zakhidov <i>et al.</i> , Modifying Cytogenetic Effects of Gossypol and Derivatives, Library National Institutes of Health (1994)		
	83	Yerukhimov, Treatment of Bladder Tumors With Gossypol And Ionol In Combination With Surgical Intervention, Issues in Oncology, XI (1966)		
	84	Kuznezova <i>et al.</i> , Pharmacol. Toxicol., Boston Library Boston Spa (1979)		
	85	Zhong <i>et al.</i> , National Library of Medicine, 2:159-161 (1982)		
	86	Zhang <i>et al.</i> , Inhibitory effects (-)-gossypol on proliferation and keratinocyte growth factor expression in human breast epithelial cells, stromal cells, and adipocytes, American Association for Cancer Research 38:218 (1997)		
	87	Zheng <i>et al.</i> , Gossypol (GP) Stimulates Transforming Growth Factor Beta (TGF- $\beta$ ) Gene Expression in Human Breast Cancer Cell Line, The FASEB Journal 10:A757 (1996)		
	88	Zheng <i>et al.</i> , Studies on the Resolution of Racemic Gossypol, ACTA Pharmaceutica Sinica 25(6):430-434 (1990)		
Examiner: <i>T. Nichols</i>		Date Considered: 10/29/08		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include/copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
34	90	Adlakha <i>et al.</i> , Inhibition of DNA Polymerase $\alpha$ And Ribonucleotide Reductase by By Gossypol, Proceedings of AACR 26:249:982 (1985)		
	91	Akhila <i>et al.</i> , Biosynthesis of Gossypol in <i>Thespesia Populnea</i> , Phytochemistry 33:335-340 (1993)		
	92	Badria <i>et al.</i> , Antimitotic Activity of Gossypol and Gossypolone, Pharmaceutical Biology, 39:120-126 (2001)		
	93	P. Baille <i>et al.</i> , Clin. Cancer Res., 3:1535-1538 (1997)		
	94	Balci <i>et al.</i> , Gossypol induced apoptosis in the human promyelocytic cell line HL60, Cytogenet Cell Genet 85:5-181 (1999)		
	95	Balci <i>et al.</i> , Gossypol Induced Apoptosis in the Human Promyelocytic Leukemia Cell Line HL 60, Tohoku J. Exp. Med. 189:51-57 (1999)		
	96	Band <i>et al.</i> , Antiproliferative Effect Of Gossypol and Its Optical Isomers on Human Reproductive Cancer Cell Lines, Gynecologic Oncology 32:273-277 (1989)		
	97	Band <i>et al.</i> , Cytocidal Effects of Gossypol and Its Optical Isomers on Reproductive Cancer Cell Lines, Gynecologic Oncology 23:261 (1986)		
	98	Benz <i>et al.</i> , Lactic Dehydrogenase Isozymes, $^{31}\text{P}$ Magnetic Resonance Spectroscopy, and In Vitro Antimitochondrial Tumor Toxicity with Gossypol and Rhodamine-123, J. Clin. Invest. 79:517-523 (1987)		
	99	Benz <i>et al.</i> , Selective Toxicity of Gossypol Against Epithelial Tumors and its Detection by Magnetic Resonance Spectroscopy, Contraception 37:221-229 (1988)		
	100	Benz <i>et al.</i> , Gossypol Enantiomers (+, -) Differentially Uncouple Tumor Mitochondria, Block Glutathione-S-Transferase Acitivity, and Inhibit Cellular Proliferation, Proceedings of AACR 29:322 (1988)		
	101	Benz <i>et al.</i> , Biochemical Correlates of the Antitumor and Antimitochondrial Properties of Gossypol Enantiomers, Molecular Pharmacology 37:840-847 (1990)		
	91102	Benz <i>et al.</i> , Gossypol Effects on Endothelial Cells and Tumor Flow, Life Sciences 49:67-72 (1991)		
	103	Blackstaffe <i>et al.</i> , Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines, Melanoma Research 7:364-372 (1997)		
	104	Bourinbaiar <i>et al.</i> , Comparative in vitro study of contraceptive agents with anti-HIV activity: <i>Gramicidin, nonoxynol-9, and gossypol</i> , Contraception 49:131-137 (1994)		
	105	Brandes <i>et al.</i> , New Drugs in Recurrent High Grade Gliomas, Anticancer Research 20:1913-1920 (2000)		
	106	Brandes <i>et al.</i> , New therapeutic agents in the treatment of recurrent high-grade gliomas, FORUM Trends in Experimental and Clinical Medicine 10:121-131 (2000)		
	107	R. Bruno <i>et al.</i> , J. Clin. Oncol., 16:187-196 (1998)		
	108	Bushunow <i>et al.</i> , Gossypol Treatment of Recurrent Adult Malignant-Gliomas, Proceedings of ASCO, 14:282 (1995)		
	109	Bushunow <i>et al.</i> , Gossypol Treatment of recurrent adult malignant gliomas, Journal of Neuro-Oncology 43:79-86 (1999)		
	110	Chang <i>et al.</i> , Antiproliferative and Antimetastatic Effects of Gossypol (GP) on Mat-LyLu-Bearing Rats, FASEB Journal, 6:3794 (1992)		
	111	Chang <i>et al.</i> , Prostate, begin hypertrophy and prostatic carcinoma: A study of cell biology of prostate and chemotherapy for prostatic hypertrophy and prostatic cancer, Dissertation Abstract International, 55:4330-B (1995)		
	112	Chang <i>et al.</i> , Potential of Gossypol (GP) and Transforming Growth Factor- $\beta$ , (TGF- $\beta$ ) as Inhibitors of Canine Prostate Growth, FASEB Journal, 9:4813-4814 (1995)		
	113	Chang <i>et al.</i> , Antiproliferative and Antimetastatic Effects of Gossypol on Dunning Prostate Cell-Bearing Copenhagen Rats, Research Communications in Chemical Pathology and Pharmacology 79:293-312 (1993)		
	114	Chen <i>et al.</i> , Application of 2D NMR Techniques in the Structure Determination of Ganosporelactone A and B, ACTA Pharmaceutica Sinica 26:430-436 (1991)		
	115	Coyle <i>et al.</i> , <i>In-Vitrop</i> and <i>in vivo</i> cytotoxicity of gossypol against central nervous system tumor cell lines, Journal of Neur-Oncology 19:25-35 (1994)		
34	116	Dallacker <i>et al.</i> , Über Gossypol- und Hemigossypol-Derivate - Darstellung von Hydroxy-methyl-naphto[1,3]dioxolen, Chemiker-Zeitung 13:5-11 (1989)		
Examiner:	<i>V. armenakis</i>		Date Considered:	<i>10/29/05</i>
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
84	117	Dallacker <i>et al.</i> , Darstellung von Methyl-isopropyl-naphthol-derivaten durch Pd-katalysierte Cyclocarbonylierung, Chemiker-Zeitung 114:144-147 (1990)		
	118	Dao <i>et al.</i> , Synthesis and cytotoxicity of gossypol related compounds, Eur. J. Med. Chem. 35:805-813 (2000)		
	119	Darzynkiewicz <i>et al.</i> , Cytometry in Cell Necrobiology: Analysis of Apoptosis and Accidental Cell Death (Necrosis), Cytometry 27:1-20 (1997)		
	120	Data <i>et al.</i> , A Study of the Derivatives of (+)-Gossypol, Indian Journal of Chemistry 10:691-693 (1972)		
	121	Davila <i>et al.</i> , Toxicological Studies of Gossypol in Primary Culture of Postnatal Rat Hepatocytes, Journal of Molecular and Cellular Toxicology, 4:161-170 (1991)		
	123	Deck <i>et al.</i> , Gossypol and Derivatives: A New Class of Aldose Reductase Inhibitors, J. Med. Chem. 34:3301-3305 (1991)		
	124	DeMartino <i>et al.</i> , Electron microscopic and biochemical studies of the effect of Gossypol on Ehrlich ascites tumor cells, Caryologia, International Journal of Cytology, Cytosystematics and Cytogenetics 35:114-115 (1982)		
	125	de Peyster <i>et al.</i> , Genetic toxicity studies of gossypol, Mutation Research 197:293-312 (1993)		
	126	De-yu <i>et al.</i> , Mutagenicity of gossypol analyzed by inductio of meiotic micronuclei in vitro, Mutation Research 208:69-72 (1988)		
	127	Dhaliwal <i>et al.</i> , Cytogenetic Analysis of a Gossypol-Induced Murine Myxosarcoma, Journal of the National Cancer Institute, 78:1203-1209 (1987)		
	128	A. Degterev <i>et al.</i> , Nat. Cell Biolog., 3:173-182 (2001)		
	129	Dogliotti <i>et al.</i> , Cytotoxic chemotherapy for adrenocortical carcinoma, Minerva Endocrinologica, 20:105-109 91995)		
	130	Edwards <i>et al.</i> , Sysnthesis of Gossypol and Gossypol Derivatives, Journal of the American Oil Chemists' Society 47:441-442 (1970)		
	131	Finaly <i>et al.</i> , Mechanism of the Gossypol Inactivation of Pepsinogen, Journal of Biological Chemistry 248:4827-4833 (1973)		
	132	Fish <i>et al.</i> , The Photo-epimerisation of Gossypol Schiff's Bases, Tetrahedron: Asymmetry 6:873-876 (1995)		
	133	Flack <i>et al.</i> , Treatment of adrenocortical carcinoma with gossypol, Proceedings of American Association for Cancer Research 31:198 (1990)		
	134	Flack <i>et al.</i> , Oral Gossypol in the Treatment of Metastatic Adrenal Cancer, Journal of Clinical Endocrinology and Metabolism, 76:1019-1024 (1993)		
	135	Floridi <i>et al.</i> , The Effect of the Association of Gossypol and Lonidamine on the Energy Metabolism of Ehrlich Ascites Tumor Cells, Experimental and Molecular Pathology 38:322-335 (1983)		
	136	Floridi <i>et al.</i> , The Effect of Gossypol and Lonidamine on Electron Transport in Ehrlich Ascites Tumor Mitochondria, Experimental and Molecular Pathology 40:246-261 (1984)		
	137	Ford <i>et al.</i> , Modulatio nof resistance of alkylating agents in cancer cell by gossypol enantiomers, Cancer Letters 56:85-94 91991)		
	138	Gilbert <i>et al.</i> , Antiproliferative Activity of Gossypola nd Gossypolone on Human Breast Cancer Cells, Life Sciences 57:61-67 (1995)		
	139	Gonzalez-Garza <i>et al.</i> , Cytotoxic Effects of Gossypol and Vitamin E on Human and Rat Lymphocytes and Spermatozoa, Nutrition Reports International (1995)		
	140	Gorczyca <i>et al.</i> , The Cell Cycle Related Differences in Susceptibility of HL-60 Cells to Apoptosis Induced by Various Antitumor Agents, Cancer Research 53:3186-3192 (1993)		
	141	Grankvist, Gossypol-Induced Free Radical Toxicity to Isolated Islet Cells, Int. J. Biochem. 21:853-856 (1989)		
	142	Hamasaki <i>et al.</i> , Gossypol, a potent inhibitor of arachidonate 5- and 12-lipoxygenases, Biochimica et Biophysica Acta 834:37-41 (1985)		
	143	Han <i>et al.</i> , Gossypol in the Treatment of Endometriosis and Uterine Myoma, Chontr. Gynec. Obstet. 16:268-270 (1987)		
	144	Haroz <i>et al.</i> , Tumor Initiating And Promoting Activity of Gossypol, Toxicology letters, 72 (1980)		
84	145	Haspel <i>et al.</i> , Cytocidal Effect of Gossypol on Cultured Murine Erythroleukemia Cells is Prevented by Serum Protein, Journal of Pharmacology and Experimental Therapeutics 229:218-225 (1984)		
Examiner:	<i>Tashen H</i>		Date Considered:	<i>10/29/05</i>
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
<i>SH</i>	146	J. Hirth <i>et al.</i> , Clin. Cancer Res., 6:1255-1258 (2000)		
	147	Heinstein <i>et al.</i> , The Biosynthesis of Gossypol, Biochemistry 28:1342-B (1967)		
	148	Hendricks <i>et al.</i> , Hepatocarcinogenicity of Glandless Cottonseeds and Cottonseed Oil to Rainbow Trout ( <i>Salmo gairdnerii</i> ), Science 208:309-311 (1980)		
	149	Herve <i>et al.</i> , Contraceptive gossypol blocks cell-to-cell communication in human and rat cells, European Journal of Pharmacology 313:243-255 (1996)		
	150	Hong <i>et al.</i> , Study of the Effects of Acetate Gossypol, High Energy Shock Waves (HESW) and Their Combination on the Human Bladder Cancer Cell Line BT <sub>5627</sub> , ACTA Anatomica Sinica 25:291-296- (1994)		
	151	Hu <i>et al.</i> , Gossypol Effects on Cultured Normal and Malignant Melanocytes, In Vitro Cellular & Development Biology 22:583-588 (1986)		
	152	Hu <i>et al.</i> , Gossypol Inhibits Basal And Estrogen (E <sub>2</sub> )-Stimulated DNA Synthesis in Human Breast Carcinoma (HBC) Cells, FASEB Journal, 7:3982 (1993)		
	153	Hu <i>et al.</i> , Gossypol Inhibits Basal And Estrogen-Stimulated DNA Synthesis in Human Breast Carcinoma Cells, Life Sciences 53:433-439 (1993)		
	154	Hu <i>et al.</i> , Presence of antitumor activities in the milk collected from gossypol-treated dairy cows, Cancer Letters 87:17-23 (1994)		
	155	Huang <i>et al.</i> , Resolution of Racemic Gossypol, Journal of Ethnopharmacology 20:13-20 (1987)		
	156	Huchinson <i>et al.</i> , The mechanism of gossypol acetic acid cytotoxicity, Dissertation Abstracts International, 59:1612-B (1998)		
	157	Hutchinson <i>et al.</i> , Attenuation of Gossypol Cytotoxicity by Cyclic AMP in a Rat Liver Cell Line, Toxicology and Applied Pharmacology 151:311-318 (1998)		
	158	Jaroszewski <i>et al.</i> , Action of Gossypol and Rhodamine 123 on Wild type and Multidrug-resistant MCF-7 Human Breast Cancer Cells: <sup>31</sup> P Nuclear Magnetic Resonance and Toxicity Studies, Cancer Research 50:6936-6943 (1990)		
	159	Jarvis <i>et al.</i> , INDuction of Apoptotic DNA Fragmentation and Cell Death in HL-60 Human Promyelocytic Leukemia Cells by Pharmacological Inhibitors of Protein Kinase C, Cancer Research 54:1707-1714 (1994)		
	160	Jiang <i>et al.</i> , Inhibitory Action of Gossypol on the Growth of MAT-LyLu Prostate Cancer Cells is Associated with Stimulation of Transforming Growth Factor-β <sub>1</sub> (TGF-β <sub>1</sub> ), Biology of Reproduction 60:252		
	161	Jiang <i>et al.</i> , Differing Effects of Gossypol on MAT-LYLU Cells and MAT-LYLU Cells Isolated From Metastasized Lung of MAT-LYLU Cell-Bearing Copenhagen Rats, Society for the Study of Reproduction 58:89		
	162	Jiang <i>et al.</i> , The Effects of Gossypol on the Invasiveness of MAT-LyLu Cells and MAT-LyLu Cells from the Metastasized Lungs of MAT-LyLu-Bearing Copenhagen Rats, Anticancer Research 20:4591-4598 (2000)		
	163	Jia-xin <i>et al.</i> , Studies on the Synthesis of Gossypol Derivatives and Their Antifertility Action, Reproduction and Contraception 6:48:51 (1986)		
	164	Joingshang <i>et al.</i> , Of Gossypol in Mice, Rats and Human Tumor Cell Lines and Its Possible Mechanism, ACTA Academiae Medicinae Sinicase 8:486-488 (1986)		
	165	Jolad <i>et al.</i> , Tumor-Inhibitory Agent from <i>Montezuma speciosissima</i> (Malvaceae), Journal of Pharmaceutical Sciences 64:1889-1890 (1975)		
	166	Joseph <i>et al.</i> , Cytotoxicity of enantiomers of gossypol, Br. J. Cancer 54:511-513 (1986)		
	167	Jung <i>et al.</i> , Recent Studies on Natural Products as Anti-HIV Agents, Current Medicinal Chemistry 7:649-651 (2000)		
	168	Kai <i>et al.</i> , Resolution of Racemic Gossypol, J. Chem. Soc., Chem. Commun. 3:168:169 (1985)		
	168	Kaplan <i>et al.</i> , Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies, Breast Cancer Research and Treatment 31:285-299 (1994)		
<i>SH</i>	170	Keller <i>et al.</i> , Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor, Journal of Molecular Graphics and Modelling 5346:1-9 92002)		
Examiner: <i>Parthasarathy</i>	Date Considered: 10/29/05			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
<i>SM</i>	171	Keniry <i>et al.</i> , Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) in the Evaluation of Tumor Growth and Chemotherapy Response, Proceedings of AACR 27:384 (1986)		
	172	Keniry <i>et al.</i> , The Effect of Gossypol and 6-Aminonicotinamide on Tumor Cell Metabolism: A <sup>31</sup> P-Magnetic Resonance Spectroscopic Study, Biochemical and Biophysical Research Communications 164:947-953 (1989)		
	173	Kim <i>et al.</i> , Comparative <i>In Vitro</i> Spermicidal Effects of (+)-Gossypol, (-)-Gossypol and Gossypolone, Contraception 30:253-259 (1984)		
	174	Koll <i>et al.</i> , A Phase I Study of Gossypol (GP) in HIV-Infected Patients (pts) in Mexico, Abstracts of the 33rd ICAC 245-687		
	175	Koryakin <i>et al.</i> , Ultrasound investigation of blood supply in scrotal organs, 10th World Congress on Human Reproduction 307 (1999)		
	176	Latronico <i>et al.</i> , Extensive Personal Experience Adrenocortical Tumors, Journal of Clinical Endocrinology and Metabolism 82:1317-1324 (1997)		
	177	LaVoie <i>et al.</i> , Investigation of Intracellular Signals Mediating the Anti-Apoptotic Action of Prolactin in Nb2 Lymphoma Cells, Society for Experimental Biology and Medicine 257:269 (1995)		
	178	Lee, Novel Antitumor Agents from Higher Plants, Medical Research Reviews, 19:569-596 (1999)		
	179	Lee <i>et al.</i> , Plant Phenolic Compounds as Cytotoxic Antitumor Agents, American Chemical Society 29:367-379 (1992)		
	180	Lefeng <i>et al.</i> , Clinical Effects and Experimental Study on Gossypol in Endometriosis, Chin. J. Integr. Med. 9(8):451-464 (1989)		
	181	Levine, Inhibition of the A-23187-Stimulated Leukotriene And Prostaglandin Biosynthesis of Rat Basophil Leukemia (RBL-1) Cells By Non-Steroidal Anti-Inflammatory Drugs, Anti-Oxidants, and Calcium Channel Blockers, Biochemical Pharmacology 32:3023-3025 (1983)		
	182	Li <i>et al.</i> , DNA-Breaking Versus DNA-Protecting Activity of Four Phenolic Compounds <i>in vitro</i> , Free Rad. Res. 33:551-566 (2000)		
	183	Llian <i>et al.</i> , Hepatoma Initiating and Promoting Effects of Gossypol, ACTA Academiae Medicinae Sinicae (1985)		
	184	Liang <i>et al.</i> , Developing gossypol derivatives with enhanced antitumor activity, Investigational New Drugs 13:181-186 (1995)		
	185	Liqueros <i>et al.</i> , The antiproliferative Effects of Gossypol and the Retinoblastoma Gene Protein, Clinical Pharmacology & therapeutics 57:206 (1995)		
	186	Liqueros <i>et al.</i> , Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells, British Journal of Cancer 76(1):21-28 (1997)		
	187	Lin <i>et al.</i> , Selective Inhibition of Human Immunodeficiency Virus Type 1 Replication by the (-) but Not the (+) Enantiomer of Gossypol, Antimicrobial Agents and Chemotherapy, 2149-2151 (1989)		
	188	Lin <i>et al.</i> , Anti-HIV-1 Activity and Cellular Pharmacology of Various Analogs of Gossypol, Biochemical Pharmacology 46:251-255 (1993)		
	189	Lin <i>et al.</i> , Gossypol and tamoxifen prevent estrogen-induced renal carcinogenesis in hamsters, Proceedings of the American Association for Cancer Research 36:391-2329 (1995)		
190	Majumdar <i>et al.</i> , Genotoxic Effects of Gossypol Acetic Acid on Cultured Murine Erythroleukemia Cells, Environmental and Molecular Mutagenesis 18:212-219 (1991)			
191	Matlin <i>et al.</i> , Large-Scale Resolution of Gossypol Enantiomers for Biological Evaluation, Contraception 37:229-237 (1988)			
192	McSheehy <i>et al.</i> , Gossypol, a cytotoxic agent, may uncouple respiration of Ehrlich ascites tumour cells, Biochemical Society Transactions 16:616-617 (1988)			
193	Meiling, Gossypol Treatment for Menopausal Functional Bleeding, Myoma of Uterus and Endometriosis - Preliminary Report, ACTA Academiae Medicinae Sinicae 2:167-169 (1980)			
194	Meltzer <i>et al.</i> , A Regioselective Route to Gossypol Analogues: The Synthesis of Gossypol and 5,5'-Didesisopropyl-5,5'-diethylgossypol, J. Org. Chem. 50:3121-3124 (1985)			
195	Fujii <i>et al.</i> , "Effect of cerulenin, an inhibitor of fatty acid synthesis, on the immune cytotoxicity of tumor cells" Jpn. J. Exp. Med 1986 Jun;56(3):99-106 (Abstract only)			
196	Gossypol, Xian Oil 7 Fat Works, Drugs of the Future, vol. 21, no. 5, 1996			
197	<i>SM</i> Meyers <i>et al.</i> , The synthesis of (S)-(+)gossypol via an asymmetric Ullmann coupling, Chem. Commun., 1573-1584 (1997)			
Examiner: <i>John H</i>	Date Considered:	10/29/05		
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>				
SN	198	Moh <i>et al.</i> , Effect of Gossypol (GP) on a 5 $\alpha$ -Reductase and a 3 $\alpha$ -Hydroxysteroid Dehydrogenase (3 $\alpha$ -HSD) in Adult Rat Testes, FASEB Journal 6:342 (1992)		
	199	Mohan, Problems and Perspectives in the Design of Anti-HIV-I Agents, Drug Development Research 29:1-17 (1993)		
	200	S.W. Muchmore <i>et al.</i> , Nature, 381:335-341 (1996). , and .		
	201	Mushtaq <i>et al.</i> , Gossypol (GP) Inhibits in Vitro Porcine Oocyte Maturation and Early Embryonic Development in Modified Simple Media, Society for the Study of Reproduction, 52:172 (1998)		
	202	Naik <i>et al.</i> , Preclinical studies of gossypol in prostate carcinoma, International Journal of Oncology 6:209-213 (1995)		
	203	Nayak <i>et al.</i> , Induction of Sister Chromatid Exchanges and Chromosome Damage by Gossypol in Bone Marrow Cells of Mice, Teratogenesis, Carcinogenesis, and Mutagenesis 6:83-91 (1986)		
	204	Newman <i>et al.</i> , Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors, Cancer Chemother Pharmacol 39:254-258 (1997)		
	205	Ng <i>et al.</i> , Anti-Human Immunodeficiency virus (ANTI-HIV) Natural Products with Special Emphasis on HIV Reverse Transcriptase Inhibitors, Life Sciences 61:933-949 (1997)		
	206	Ognyanov <i>et al.</i> , Synthesis of Gossypol Analogues, Helvetica Chimica ACTA 72:353-360 (1989)		
	207	Ohuchi <i>et al.</i> , Inhibition of gossypol of tumor promoter-induced arachidonic acid metabolism in rat peritoneal macrophages, Biochimica et Biophysica Acta, 971:85-91 (1988)		
	208	Olgiati <i>et al.</i> , Gossypol Inhibition of Adenylate Cyclase, Archives of Biochemistry and Biophysics 231:411-415 (1984)		
	209	Papageorgiou <i>et al.</i> , A New Method for the Isolation of Gossypol From Cottonseed-Oil Fatty Acids, Chimika Chronika 7:101-109 (1978)		
	210	Perez <i>et al.</i> , Studies on spermatogenesis and apoptosis in the bovine, Dissertation Abstracts International 50:526-B (1999)		
	211	Phung <i>et al.</i> , Isolation and Purification of Gossypol in Cotton Seeds of Vietnam, Tap chi Hoa hov, 35:91-93 (1997)		
	212	Pirogov <i>et al.</i> , Postoperative Bronchopleural Complications in Combined Treatment of Pulmonary Cancer, Issues of Oncology, 20:24-28 (1974)		
	213	Polsky <i>et al.</i> , Inactivation of Human Immunodeficiency Virus (RIV) By Gossypol (GP), Clinical Research 35(3):487A (1987)		
	214	Polsky <i>et al.</i> , Inactivation of Human Immunodeficiency Virus in Vitro by Gossypol, Contraception, 39:579-587 (1989)		
	215	Przybylski <i>et al.</i> , Spectroscopic studies and PM5 semiempirical calculations of new Schiff bases of gossypol with amino derivatives of crown ethers, Journal of Molecular Structure, 16:04-1-9 (2002)		
	216	Qian, Gossypol: A Potential Antifertility Agent for Males, Ann. Rev. Pharmacol. Toxicol. 24:329-60 (1984)		
	217	Qui <i>et al.</i> , The Search for Gene(s) Conferring Sensitivity to Cell Killing by Gossypol, The FASEB Journal 13:A151A (1999)		
	218	J. O'Quigley <i>et al.</i> , Biometrics 46:33-48 (1990)		
	219	Quintana <i>et al.</i> , Gossypol-induced DNA breaks in rat lymphocytes are secondary to cytotoxicity, Toxicology Letters 117:85-94 (2000)		
	220	Rao <i>et al.</i> , Antitumor effects of gossypol on murine tumors, Cancer Chemother Pharmacol. 15:20-25 (1985)		
	221	Razakantoanina <i>et al.</i> , Antimalarial activity of new gossypol derivatives, Parasitol Res. 86:665-668 (2000)		
	222	Reidenberg, Studies of gossypol in the treatment of cancer, Reproductive Medicine, 305-308		
	223	Reidenberg <i>et al.</i> , Gossypol Treatment of Metastatic Adrenal Cancer, Clinical Pharmacology and Therapeutics, 51:PI-96 (1992)		
	224	Rekha <i>et al.</i> , Inhibition of Human Class 3 Aldehyde Dehydrogenase, and Sensitization of Tumor Cells that Express Significant Amounts of this Enzyme to Oxazaphosphorines, by the Naturally Occurring Compounds Gossypol, Enzymology and Molecular Biology of Carbonyl Metabolism 6, 133-146 (1996)		
SN	225	Resnick <i>et al.</i> , Comparative Evaluation of Spermidicidal Agents with Virucidal Activity Against HIV, IX <sup>th</sup> International Conference on AIDS, 11:PO-C22-3154 (1993)		
Examiner: <i>Par Wright</i>	Date Considered: 10/29/05			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

226	Rosenberg <i>et al.</i> , Biochemical Basis for the Gossypol-induced Inhibition of DNA Replication in Mammalian Cells, American Association for Cancer Research, 29:1291 (1988)
227	Royer <i>et al.</i> , Inhibition of Human Immunodeficiency Virus Type I Replication by Derivatives of Gossypol, Pharmacological Research, 24:407-412 (1991)
228	G. Rassidakis <i>et al.</i> , Amer. J. Path., 159:527-535 (2001)
229	J.C. Reed <i>et al.</i> , Ann. Oncol., 5:61-65 (1994)
230	Sampath <i>et al.</i> , A Rapid Procedure for the Resolution of Racemic Gossypol, J. Chem. Soc., Chem. Commun., 649-650 (1986)
231	Schinazi <i>et al.</i> , Insights Into HIV Chemotherapy, AIDS Research and Human Retroviruses, 8:963-990 (1992)
232	A.F. Schott <i>et al.</i> , Oncogene, 11:1389-1394 (1995)
234	Seidman <i>et al.</i> , Gossypol in Advanced Breast Cancer, Journal of Investigative Medicine 46:213A (1998)
235	Seidman, Chemotherapy for Advanced Breast Cancer: A Current Perspective, Seminars in Oncology, 23:55-59 (1996)
236	Shelly <i>et al.</i> , Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cells lines, Cancer Letters, 135:171-180 (1999)
237	Shelly <i>et al.</i> , Structure-activity studies on gossypol in tumor cell lines, Anti-Cancer Drugs, 11:209-216 (2000)
238	S. Shi <i>et al.</i> , J. Histochem. Cytochem., 39:741-748 (1991)
239	Shidaifat <i>et al.</i> , Differential regulation of gene expression by gossypol: A potential inhibitor of prostate cell growth, Dissertation Abstracts International, 57:6097-B (1997)
240	Shidaifat <i>et al.</i> , Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor- $\beta$ , Cancer Letters 107:37-44 (1996)
241	Shidaifat <i>et al.</i> , Gossypol Arrests Human Benign Prostatic Hyperplastic Cell Growth at G0/G1 Phase of the Cell Cycle, Anticancer Research 17:1003-1010 (1997)
242	Sinnhuber <i>et al.</i> , Dietary Factors and Hepatoma in Rainbow Trout ( <i>Salmo gairdneri</i> ). I. Cocarcinogenesis by Cyclopropenoid Fatty Acids and the Effect of Gossypol and Altered Lipids on Aflatoxin-Induced Liver Cancer, Journal of the National Cancer Institute, 41:1293-1299 (1968)
243	Stein <i>et al.</i> , A preliminary clinical study of gossypol in advanced human cancer, Cancer Chemother Pharmacol 30:480-481 (1992)
244	Sugimoto <i>et al.</i> , Differential proliferative responses to the (-)-enantiomer of gossypol in cultured human breast epithelial and stromal cells, American Association for Cancer Research 40:4 (1999)
245	Tai, Rat Basophilic Leukemia-1 Cell Possesses 12-Lipoxygenase and 5-Lipoxygenase activities which are specifically inhibited by gossypol acetic acid, Japanese Journal of Allergology 33:1040-1046 (1984)
246	Tan <i>et al.</i> , Evaluation of Natural Products As Inhibitors of Human Immunodeficiency Virus Type I (HIV-1) Reverse Transcriptase <sup>1</sup> , Journal of Natural Products, 54:143-154 (1991)
247	Tanphaichitr <i>et al.</i> , Direct Effect of Gossypol on TR-ST Cells: Perturbation of Rhodamine 123 Accumulation in Mitochondria, Biology of Reproduction, 31:1049-1060 (1984)
248	Tao <i>et al.</i> , The Effects of Gossypol on Human BPH Cells <i>In Vitro</i> , 21:31 (1994)
249	Teng <i>et al.</i> , c-MYC Protein Expression in Spermatocytes During Gossypol-Induced Apoptosis, Molecular Biology of the Cell, 364a:2116 (1997)
250	Teng <i>et al.</i> , Biphasic c-Myc Protein Expression During Gossypol-Induced Apoptosis in Rat Spermatocytes, Contraception 57:117-123 (1998)
251	Teng, C-Fos Protein Expression in Apoptotic Rat Spermatocytes Induced by Gossypol, Contraception 57:281-286 (1998)
252	Thoenes <i>et al.</i> , Cytotoxic Effects of Adriamycin, Bleomycin, Gossypol and Hydroxyanisole to Cultured Human Malignant Melanoma Cells, Journal of Cancer Research and Clinical Oncology, 113:D-THER:12, S46 (1987)
253	Thomas <i>et al.</i> , Effects of Gossypol on the Cell Cycle Phases in T-47D Human Breast Cancer Cells, Anticancer Research 11:1469-1476 (1991)

Examiner:

Date Considered:

10/29/05

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-08477	Serial No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Shaomeng Wang <i>et al.</i>		
		Filing Date:	Group Art Unit:	
(37 CFR § 1.98(b))				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
SN	254	D.K. Trask <i>et al.</i> , Laryngoscope, 112:638-644 (2002)		
	255	Troll <i>et al.</i> , Free Oxygen Radicals: Necessary Contributors to Tumor Promotion and Cocarcinogenesis, Proceedings of the 14th International Symposium of The Princess Takamatsu Cancer Research Fund, 207-218 (1984)		
	256	Tso, Gossypol Inhibits Ehrlich Ascites Tumor Cell Proliferation, Cancer Letters 24:257-261 (1984)		
	257	Tuszynski <i>et al.</i> , Differential Cytotoxic Effect of Gossypol on Human Melanoma, Colon Carcinoma, and Other Tissue Culture Cell Lines, Cancer Research 44:768-771 (1984)		
	258	Vander Jagt <i>et al.</i> , Gossypol: Prototype of Inhibitors Targeted to Dinucleotide Folds, Current Medicinal Chemistry 7:479-498 (2000)		
	259	Van Poznak <i>et al.</i> , Oral Gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial, Breast Cancer Research and Treatment 66:239-248 (2001)		
	260	Vlietinck <i>et al.</i> , Plant-Derived Leading Compounds for Chemotherapy of Human Immunodeficiency Virus (HIV) Injection, PlantaMedica 64:97-109 (1998)		
	261	Wang <i>et al.</i> , Effect of Gossypol on DNA Synthesis and Cell Cycle Progression of Mammalian Cells <i>in Vitro</i> , Cancer Research 44:35-38 (1984)		
	262	Wang <i>et al.</i> , Cytotoxic effect of gossypol on olonn carcinoma cells, Life Sciences 67:2663-2671 (2000)		
	263	P. Watkins, Pharmacogenetics, 4:171-184 (1994)		
	264	Wichmann <i>et al.</i> , Inhibiting herpes simplex virus type 2 infection in human epithelial cells by gossypol, a potent spermicidal and contraceptive agent, Am. J. Obstet. Gynecol. 142:593-594 (1982)		
	265	Wu <i>et al.</i> , Pharmacokinetics of (+)-, and (+)-, and (-)-gossypol in humans and dogs, Clinical Pharmacology & Therapeutics 39:613-618 (1996)		
	266	Wu <i>et al.</i> , An <i>in Vitro</i> and <i>in Vivo</i> Study of Antitumor Effects of Gossypol on Human SW-13 Andrenocortical Carcinoma, Cancer Research 49:3743-3758 (1989)		
	267	Wu <i>et al.</i> , In vitro antitumor activity of gossypol alone or in combination with amsacrine, European Journal of Pharmacology 183:230 (1990)		
	268	Xueqing <i>et al.</i> , Clinical Observation and Experimental Study of Gossypol in Treatment of Dysfunctional Menorrhagia, Endometriosis and Fibromyoma of Uterus, Chinese Journal of Integrated Traditional and Western Medicine 8:197 (1988)		
	269	Ye <i>et al.</i> , The Modulation of Gap Junctional Communication by Gossypol in Various Mammalian Cell Lines <i>in Vitro</i> , Fundamental And Applied Toxicology 14:817-832 (1990)		
	270	Ye <i>et al.</i> , Toxicity of a Male Contraceptive, Gossypol, in Mammalian Cell Cultures, <i>In Vitro</i> 19:53-57 (1983)		
	271	Yikang <i>et al.</i> , Studies on Resolution of Racemic Gossypol, Scientia Sinica 30:297-303 (1987)		
	272	Ying <i>et al.</i> , Studies on Frequencies of Sister Chromatid Exchange in Peripheral Blood Lymphocytes Before and After Gossypol Treatment, Proc. DAMS and PUMC 1:34-36 (1986)		
	273	Youfang <i>et al.</i> , Ultrastructural Changes of Smooth Muscle Cells in Leiomyoma and Myometrium of Human Uterus after Gossypol Treatment, ACTA Academiae Medicinae Sinicae, 9:299-301 (1987)		
	274	Yu, Probing Into the Mechanism of Action, Metabolism and Toxicity of Gossypol by Studying its (+)- And (-)- Stereoisomers, Journal of Ethnopharmacology 20:65-78 (1987)		
SN	275	Zhang <i>et al.</i> , The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor $\beta_1$ production, International Journal of Oncology 13:1291-1297 (1998)		
Examiner: <i>Takayama</i>	Date Considered:	10/29/05		
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



Sheet 1 of 1



FORM PTO-1449 (Modified) Department of Commerce Patent and Trademark Office					Attorney Docket No.: UM-08477		Serial No.: 10/729,156	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary) (37 CFR § 1.98(b))								
					Applicant: Shaomeng Wang <i>et al.</i> Filing Date: 12/5/03		Group Art Unit:	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patente	Class	Subclass	Filing Date	
SJH	1	3,647,791	03/7/72	Rossi <i>et al.</i>	260	268	09/19/67	
<b>FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS</b>								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
SJH	2	WO 97/40015	30 Oct 1997	PCT			Yes	
SJH	3	WO 96/04250	15 Feb 1996	PCT			No	
SJH	4	WO 94/20497	15 Sept 1994	PCT				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>								
SJH	5	Boyfield <i>et al.</i> , "n-(substituted-phenyl)piperazines." Bioorganic And Medicinal Chemistry Letters, 6:1227-32 (1996)						
	6	Rao, "Agents acting on the central nervous system. XIII:", Journal of Medicinal Chemistry 13:516-22 (1970)						
	7	Singh <i>et al.</i> , "Antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)2,3,4,4a,5,6-hexahydro-1(h)-pyrazinol(1,-2-a)quinoline hydrochloride", Experientia 29:1529-30 (1973)						
SJH	8	Singh <i>et al.</i> , "Pharmacological studies on 3[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6,hexahydro-1(H)pyrazinol(1,2,-a)quinoline hydrochloride (Compound 69/83)" Arrzneimittel Forschung Drug Research 28:1641-4 (1978)						
Examiner: <i>Castro</i> / <i>J. A. Castro</i> EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				Date Considered: <u>10/29/05</u>				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

<i>Complete If Known</i>	
<b>Application Number</b>	10/729,156
<b>Filing Date</b>	12/05/03
<b>First Named Inventor</b>	Wang
<b>Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	UM-08477

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SM	1	Wu et al., J. Chromatography 433:141 (1988)	
	2	Shen et al., Ch. J. Magnetic Resonance 20:373 (2003)	
	3	Meyers et al., Tetrahedron 54:10493 (1998)	
	4	Brzezinski et al., J. Mol. Structure 230:261 (1990)	
	5	Matlin et al., J. Liquid Chromatography 12:1485 (1989)	
	6	Jaroazewski et al., Chirality 4:216 (1992)	
	7	Przybylski et al., J. Mol. Structure 691:227 (2004)	
	8	Przybylski et al., J. Mol. Structure 654:167 (2003)	
	9	Przybylski et al., J. Mol Structure 569:147 (2001)	
SM	10	Haas et al., J. Org. Chem. 30:4111 (1965)	

Examiner Signature	<i>Parthasarathy</i>	Date Considered	10/29/05
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Application Number</b>	10/729,156
				<b>Filing Date</b>	12/05/03
				<b>First Named Inventor</b>	Wang
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
Sheet	2	of	2	<b>Attorney Docket Number</b>	UM-08477

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	10/29/05
-----------------------	---	--------------------	----------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/729,156
		Filing Date	12/05/03
		First Named Inventor	Wang
		Art Unit	
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	UM-08477

U. S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	10/29/05
--------------------	---	-----------------	----------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.